| Date | Title | Description |
| 11.02.2025 | PU Prime's New Website and Promotions: A Leap into the Future of Trading | In the fast-paced world of online trading, staying ahead is crucial. PU Prime, a prominent player in the fintech arena, has recently made significant strides to enhance user experience and trader confidence. With a newly redesigned website ... |
| 10.02.2025 | PU Prime Launches ‘Feather Your Trades’ Promotion to Support Traders and Enhance Confidence | Singapore, Singapore, January 14th, 2025, FinanceWire
PU Prime is launching Feather Your Trades, a promotion aimed at supporting traders in managing losses and maintaining confidence in their trading activities. Running from 15 January to 1... |
| 10.02.2025 | Bain Capital to Buy Mitsubishi Tanabe Pharma Corporation | Bain Capital, a Boston, MA-based global private investment firm, announced it has signed a definitive agreement to acquire Mitsubishi Tanabe Pharma Corporation, an Osaka, Japan-based company developing drugs, in a carve-out transaction from... |
| 08.02.2025 | Bain купит японскую Mitsubishi Tanabe Pharma за $3,4 млрд | У фирмы Mitsubishi Tanabe Pharma из Осаки есть линейка препаратов, связанных с центральной нервной системой, иммуновоспалением и онкологией. Согласно ее веб-сайту, она ведет операции в более чем дюжине мест на трех континентах за пределами ... |
| 07.02.2025 | Bain to buy Japan's Mitsubishi Tanabe Pharma for $3.4 billion | TOKYO :U.S. private equity firm Bain Capital has bought Mitsubishi Tanabe Pharma in a deal worth 510 billion yen ($3.4 billion), saying it was encouraged by prospects of regulatory change for Japan's drug industry.
The Osaka-based firm has ... |
| 20.01.2025 | Mitsubishi Chemical picks Bain as preferred bidder for subsidiary, Nikkei says | TOKYO :Mitsubishi Chemical Group picked U.S. investment fund Bain Capital as the preferred bidder for its pharmaceutical subsidiary, Tanabe Mitsubishi Pharma, the Nikkei reported on Monday.
The company is likely to sell its Tanabe Mitsubish... |
| 14.12.2024 | Niwot's Triumph: A Cross Country Championship Journey | In the world of high school sports, few stories shine as brightly as that of the Niwot Cougars. This year, they sprinted to glory, claiming the national championship at the Nike Cross in Oregon. It was a journey marked by grit, determinatio... |
| 09.12.2024 | Actinogen randomizes first US participant in XanaMIA phase 2b/3 Alzheimer's disease trial | Late-stage trial in Alzheimer's opens 10 sites in US, with results due in 2025 and 2026
Appoints US-based Chief Commercial Officer, Andrew Udell
Xanamem's unique ability to control brain cortisol draws widespread coverage in the Australian ... |
| 12.09.2024 | Mitsubishi Tanabe Pharma America to Present Latest Neurodegenerative Research at the 2024 American Neurological Association 149th Annual Meeting | Posters will highlight findings from studies evaluating investigational ND0612 in Parkinson's disease and RADICAVA ORS® (edaravone) in ALS
JERSEY CITY, N.J., Sept. 12, 2024 /PRNewswire/ -- Mitsubishi Tanabe Pharma America, Inc. (MTPA) today... |
| 07.08.2024 | I AM ALS Announces the Cures Collective to Accelerate Neurodegenerative Disease Collaboration, Awareness, & Progress | WASHINGTON, Aug. 7, 2024 /PRNewswire/ -- I AM ALS announced today the launch of the Cures Collective, a neurodegenerative condition coalition. This group of advocates and partner organizations will focus on filling gaps, strengthening colle... |
| 17.06.2024 | Mitsubishi Tanabe Pharma America Presents Final Results from the Global, Phase 3b MT-1186-A02 Post-marketing Study of RADICAVA® (edaravone) in ALS | JERSEY CITY, N.J., June 17, 2024 /PRNewswire/ -- Mitsubishi Tanabe Pharma America, Inc. (MTPA) today announced the presentation of final results from the global, multi-center, double-blind, Phase 3b MT-1186-A02 study of oral edaravone in am... |
| 17.06.2024 | Mitsubishi Tanabe Pharma America Celebrates Second Anniversary of RADICAVA ORS® (edaravone) Launch in the U.S. | JERSEY CITY, N.J., June 17, 2024 /PRNewswire/ -- Mitsubishi Tanabe Pharma America, Inc. (MTPA) today announced the two-year launch anniversary of RADICAVA ORS® (edaravone) in the U.S. Since its availability in June 2022, RADICAVA ORS has be... |
| 17.06.2024 | Mitsubishi Tanabe Pharma America Presents New Results of RADICAVA® (edaravone) for People Living with ALS at the European Network to Cure ALS (ENCALS) Meeting 2024 | Real-world analysis suggests 3.2-month survival benefit for individuals treated with RADICAVA and riluzole compared to those treated with only riluzole
No new safety concerns in final results from long-term Phase 3 safety extension study in... |
| 16.05.2024 | Mitsubishi Tanabe Pharma America Announces Presentations at XXIX World Congress on Parkinson's Disease and Related Disorders | JERSEY CITY, N.J., May 16, 2024 /PRNewswire/ -- Mitsubishi Tanabe Pharma America, Inc. (MTPA) today announced two presentations on investigational ND0612 in Parkinson's disease (PD) will be shared at the International Association of Parkins... |
| 09.05.2024 | Approximately USD 10.8 Million Invested in New Drug Development for Malaria and NTDs in Partners Including Japanese Pharma Shionogi, Mitsubishi Tanabe, and Eisai and Europe-Based Institutions | TOKYO, May 9, 2024 /PRNewswire/ -- The Global Health Innovative Technology (GHIT) Fund announced today a total investment of approximately JPY 1.64 billion (USD 10.8 million1) in four projects for the development of new drugs for malaria an... |
| 03.05.2024 | Patients on hunt for diabetes, obesity and weight-loss drugs | - |
| 24.04.2024 | Pharma exports rise around 10% to $27.9 billion, US biggest importer | - |
| 15.04.2024 | Mitsubishi Tanabe Pharma America to Present Healthcare Resource Utilization Data in RADICAVA ORS® (edaravone)-Treated ALS Patients at AMCP 2024 | JERSEY CITY, N.J., April 15, 2024 /PRNewswire/ -- Mitsubishi Tanabe Pharma America, Inc. (MTPA) today announced the presentation of one abstract in amyotrophic lateral sclerosis (ALS) at the Academy of Managed Care Pharmacy (AMCP) 2024 Annu... |
| 07.03.2024 | Mitsubishi Tanabe Pharma Historical Museum holds its first special exhibition “Japanese Soccer and the Genealo gy of Gohei Tanabe” | Mitsubishi Tanabe Pharma Co., Ltd.
Mitsubishi Tanabe Pharma Historical Museum holds its first special exhibition “Japanese Soccer and the Genealogy of Gohei Tanabe” ……
Mitsubishi Tanabe Pharma Co., Ltd. (Head Office: Chuo-ku, Osaka, Represe... |
| 05.07.2022 | EditForce and Mitsubishi Tanabe Pharma Enter into License Agreement | FUKUOKA, Japan, July 5, 2022 /PRNewswire/ -- EditForce, Inc. (Headquarters: Fukuoka, President and CEO: Takashi Ono; hereinafter "EditForce") has entered into a License Agreement (hereinafter "Agreement") with Mitsubishi... |
| 25.02.2022 | HitGen has successfully completed a three-year collaboration with MTPC to discover novel hit compounds for multiple drug targets | CHENGDU, China, Feb. 25, 2022 /PRNewswire/ -- HitGen Inc. ("HitGen"), a Shanghai Stock Exchange STAR-listed company, today announced that the company has successfully completed a three-year drug discovery research collaboration wi... |
| 19.01.2022 | ADC Therapeutics secures $30 million in new partnership deal | |
| 06.04.2021 | Mineralys Therapeutics Closes $40 Million Series A Funding | Aldosterone has been implicated as an underlying cause of hypertension in upwards of 30 percent of all hypertension patients and as such represents an ideal target for therapeutic intervention in these patients. In a Phase 1 study in health... |
| 25.04.2019 | After Biogen exit, Mitsubishi Tanabe Pharma links up with Salix to develop amiselimod; Two drug developers set up antibiotic collaboration | → About two years after Biogen $BIIB walked away from Mitsubishi Tanabe Pharma‘s MT-1303 (amiselimod), the Japanese drugmaker has joined forces with Bausch Health’s Salix Pharmaceuticals to develop the late-stage oral comp... |
| 25.09.2015 | MedImmune and Tanabe Research Laboratories have entered into a strategic collaboration | MedImmune and Tanabe Research Laboratories have entered into a strategic collaboration
25-09-2015
MedImmune, the global biologics research and development arm of AstraZeneca, and Tanabe Research Laboratories U.S.A., Inc. (TRL), a subsidiary... |
| 20.08.2014 | AstraZeneca and Mitsubishi Tanabe Pharma Corporation announce research collaboration | AstraZeneca and Mitsubishi Tanabe Pharma Corporation announce research collaboration
20-08-2014
AstraZeneca and Mitsubishi Tanabe Pharma Corporation (MTPC) today announced a three-year research collaboration in the area of diabetic nephropa... |
| 06.03.2012 | Rotavirus vaccine is lead target under Medicago, Mitsubishi Tanabe alliance | Mitsubishi Tanabe will fund R&D costs and Medicago will license rights to its vaccine technology to the pharma company. If Mitsubishi Tanabe exercises its option to license vaccines developed from the partnership, the Japanese pharma wi... |
| - | Rotavirus vaccine is lead target under Medicago, Mitsubishi Tanabe alliance | Vaccine developer Medicago (TSX:MDG) will target rotavirus, the leading cause of diarrhea in infants and children worldwide, under a new partnership with Japanese firm Mitsubishi Tanabe Pharma.
Medicago stands to gain nearly $33 million in ... |
